Bausch & Lomb wins FDA approval for Akreos implantable lens

SEPTEMBER 23, 2008 -- Bausch & Lomb (Aliso Viejo, CA) has received US Food and Drug Administration (FDA) approval to market the Akreos Advanced Optics Aspheric Lens (model AO60). The single-piece, foldable acrylic intraocular lens is designed to be aberration-free. It is implanted with a single-use device that enables one-handed insertion through an un-enlarged standard phaco incision. According to the company, this will serve as a pathway to microincision cataract surgery.

SEPTEMBER 23, 2008 -- Bausch & Lomb (Aliso Viejo, CA) has received US Food and Drug Administration (FDA) approval to market the Akreos Advanced Optics Aspheric Lens (model AO60) in the United States. The Akreos AO Lens is a single-piece, foldable acrylic intraocular lens with a four-haptic design and aspheric optics designed to be aberration-free. The lens is implanted with Bausch & Lomb's single-use AI-28 inserter, which enables single-handed insertion through an un-enlarged standard phaco incision.

Earlier this month, Bausch & Lomb announced an agreement with 20/10 Perfect Vision AG (Heidelberg, Germany) to form a joint venture focused on the laser vision correction. The company expects to begin shipping the Akreos AO Lens to surgical facilities by the end of September.

"I have been treating patients with the Akreos AO Lens for more than a year and a half in Canada and the single-piece four-haptic design allows for consistent post-op centration," said Rosa Braga-Mele, M.Ed, M.D., FRCSC. Dr. Braga-Mele serves as the director of the Cataract Unit and Surgical Teaching at Mt. Sinai Hospital in Toronto.

According to the company, the distinctive properties of the Akreos lens will serve as a pathway to microincision cataract surgery, enabling new lens technologies that can be inserted through smaller incisions.

More information:
Bausch & Lomb

More in Ophthalmology